ADVM RSI Chart
Last 7 days
-18.9%
Last 30 days
-37.2%
Last 90 days
-2.1%
Trailing 12 Months
12.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 5.9M | 5.2M | 4.4M | 3.6M |
2022 | 0 | 0 | 0 | 6.7M |
2021 | 3.6M | 5.5M | 6.5M | 7.5M |
2019 | 0 | 0 | 1.6M | 2.6M |
2018 | 7.5M | 7.6M | 7.9M | 7.5M |
2017 | 1.7M | 1.8M | 1.9M | 1.8M |
2016 | 2.4M | 2.5M | 1.9M | 1.5M |
2015 | 745.0K | 813.0K | 1.6M | 2.3M |
2014 | 210.0K | 195.0K | 369.0K | 572.0K |
2013 | 142.5K | 255.0K | 367.5K | 480.0K |
2012 | 0 | 0 | 0 | 30.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 07, 2024 | lupher, jr. mark l. | bought | 175,500 | 1.35 | 130,000 | - |
Feb 07, 2024 | scopa james paul | bought | 135,000 | 1.35 | 100,000 | - |
Sep 15, 2023 | seyedkazemi setareh | sold | -9,429 | 1.5206 | -6,201 | chief development officer |
Jun 07, 2023 | rubinstein linda m | bought | 145,490 | 1.4549 | 100,000 | chief financial officer |
Mar 15, 2023 | soparkar peter | sold | -10,442 | 0.7816 | -13,360 | chief operating officer |
Mar 15, 2023 | riley brigit | sold | -5,704 | 0.7816 | -7,299 | chief scientific officer |
Mar 15, 2023 | fischer laurent | sold | -32,232 | 0.7816 | -41,239 | ceo, president and director |
Sep 19, 2022 | beckman richard | sold | -4,569 | 1.0697 | -4,272 | chief medical officer |
Sep 19, 2022 | soparkar peter | sold | -14,232 | 1.0697 | -13,305 | see remarks section |
Sep 19, 2022 | seyedkazemi setareh | sold | -6,479 | 1.0696 | -6,058 | chief development officer |
Which funds bought or sold ADVM recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | Allworth Financial LP | sold off | -100 | -16.00 | - | -% |
Apr 25, 2024 | Bank of New York Mellon Corp | sold off | -100 | -29,821 | - | -% |
Apr 25, 2024 | GHP Investment Advisors, Inc. | new | - | 283 | 283 | -% |
Apr 25, 2024 | GHP Investment Advisors, Inc. | sold off | -100 | -151 | - | -% |
Apr 25, 2024 | Allworth Financial LP | new | - | 29.00 | 29.00 | -% |
Apr 25, 2024 | SIMPLEX TRADING, LLC | sold off | -100 | -1,000 | - | -% |
Apr 24, 2024 | Assenagon Asset Management S.A. | new | - | 5,072,290 | 5,072,290 | 0.01% |
Apr 24, 2024 | BML Capital Management, LLC | new | - | 11,780,300 | 11,780,300 | 7.77% |
Apr 24, 2024 | BML Capital Management, LLC | sold off | -100 | -3,428,440 | - | -% |
Apr 22, 2024 | Vivo Capital, LLC | new | - | 21,210,000 | 21,210,000 | 1.67% |
Unveiling Adverum Biotechnologies Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Adverum Biotechnologies Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.75 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.0B | 1.8B | -41 | 9.87 | ||||
BMRN | 15.4B | 2.5B | 74.73 | 6.21 | ||||
INCY | 11.6B | 3.7B | 19.41 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 6.0B | 396.6M | -11.37 | 15.16 | ||||
BBIO | 4.4B | - | -6.7 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.22 | 12.57 | ||||
ACAD | 2.8B | 726.4M | -44.9 | 3.79 | ||||
ARWR | 2.7B | 240.7M | -9.23 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.58 | 4.41 | ||||
NVAX | 569.6M | 983.7M | -1.05 | 0.58 | ||||
CRBP | 361.2M | 881.7K | -8.1 | 466.16 | ||||
INO | 247.0M | 4.9M | -1.83 | 50.76 | ||||
IBIO | 6.1M | 2.1M | -0.22 | 2.14 |
Adverum Biotechnologies Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2021Q1 | 2019Q4 | 2019Q3 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q1 | 2016Q4 |
Revenue | - | - | - | - | 3,600,000 | 1,800,000 | - | - | - | 7,500,000 | 5,083,333 | 2,666,667 | 250,000 | 70,000 | 833,000 | 493,000 | 6,146,000 | 461,000 | 463,000 | 463,000 | 462,000 | 488,000 |
Operating Expenses | -24.2% | 26,158,000 | 34,529,000 | 33,065,000 | 33,839,000 | 33,940,000 | 34,419,000 | 38,522,000 | 44,538,000 | 36,143,000 | - | 19,653,000 | 17,333,000 | 16,829,000 | 24,306,000 | 20,396,000 | 18,162,000 | - | - | - | - | - |
S&GA Expenses | -21.1% | 10,880,000 | 13,789,000 | 12,466,000 | 12,780,000 | 11,741,000 | 11,895,000 | 14,453,000 | 21,930,000 | 16,163,000 | - | 8,279,000 | 7,389,000 | 5,187,000 | 4,826,000 | 9,179,000 | 5,368,000 | - | - | - | - | - |
R&D Expenses | -26.3% | 15,278,000 | 20,740,000 | 20,599,000 | 21,059,000 | 22,199,000 | 22,524,000 | 24,069,000 | 22,608,000 | 19,980,000 | - | 11,374,000 | 9,944,000 | 11,642,000 | 14,480,000 | 11,217,000 | 12,794,000 | - | - | - | - | - |
EBITDA Margin | -14.4% | -31.28 | -27.34 | -24.56 | -23.38 | -22.01 | -18.78 | -17.16 | -20.14 | -24.41 | -31.19 | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | -6764.7% | -1,133,000 | 17,000 | 21,000 | 17,000 | 19,000 | - | - | - | - | - | - | - | - | -1,300,000 | - | - | - | - | - | - | - |
Earnings Before Taxes | 24.4% | -24,847,000 | -32,868,000 | -31,489,000 | -29,039,000 | -32,717,000 | -34,409,000 | -38,362,000 | -44,333,000 | -28,436,000 | - | -18,925,000 | -16,118,000 | -15,659,000 | -22,208,000 | - | - | -14,789,000 | -13,829,000 | - | - | - |
EBT Margin | -14.1% | -32.85 | -28.79 | -25.84 | -24.51 | -22.99 | -19.41 | -17.84 | -20.98 | -25.45 | -32.36 | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 27.9% | -23,714,000 | -32,885,000 | -31,510,000 | -29,056,000 | -32,736,000 | -34,409,000 | -38,362,000 | -44,333,000 | -28,436,000 | - | -18,925,000 | -16,118,000 | -15,659,000 | -20,958,000 | -18,810,000 | -17,200,000 | - | - | - | - | - |
Net Income Margin | -13.0% | -32.55 | -28.81 | -25.86 | -24.53 | -23.00 | -19.41 | -22.80 | -24.90 | -26.91 | -32.67 | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | 11.8% | -21,520,000 | -24,408,000 | -23,285,000 | -22,497,000 | -18,660,000 | -30,167,000 | -31,515,000 | -37,563,000 | -23,709,000 | -23,657,000 | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -12.1% | 173 | 197 | 241 | 276 | 308 | 332 | 375 | 407 | 440 | 491 | 526 | 462 | 483 | 508 | 331 | 349 | 223 | 206 | 210 | 221 | 213 |
Current Assets | -17.5% | 103 | 125 | 147 | 169 | 191 | 213 | 246 | 280 | 317 | 348 | 386 | 410 | 434 | 460 | 283 | 300 | 176 | 168 | 181 | 193 | 209 |
Cash Equivalents | -28.8% | 75.00 | 105 | 111 | 68.00 | 68.00 | 84.00 | 92.00 | 90.00 | 37.00 | 33.00 | 47.00 | 45.00 | 63.00 | 73.00 | 27.00 | 130 | 67.00 | 74.00 | 99.00 | 145 | 156 |
Net PPE | -4.7% | 15.00 | 15.00 | 32.00 | 33.00 | 35.00 | 37.00 | 38.00 | 37.00 | 33.00 | 37.00 | 32.00 | 28.00 | 28.00 | 27.00 | 27.00 | 27.00 | 25.00 | 15.00 | 6.00 | 4.00 | 4.00 |
Liabilities | -4.8% | 90.00 | 94.00 | 110 | 118 | 127 | 124 | 131 | 124 | 124 | 145 | 147 | 47.00 | 48.00 | 43.00 | 49.00 | 45.00 | 48.00 | 41.00 | 32.00 | 33.00 | 12.00 |
Current Liabilities | -13.7% | 25.00 | 29.00 | 45.00 | 46.00 | 32.00 | 29.00 | 31.00 | 23.00 | 21.00 | 25.00 | 21.00 | 20.00 | 21.00 | 16.00 | 21.00 | 17.00 | 19.00 | 18.00 | 10.00 | 11.00 | 11.00 |
Shareholder's Equity | -18.7% | 83.00 | 103 | 131 | 158 | 182 | 208 | 244 | 283 | 316 | 346 | 379 | 415 | 434 | 465 | 283 | 304 | 175 | 164 | 178 | 188 | 201 |
Retained Earnings | -2.6% | -919 | -896 | -863 | -831 | -802 | -769 | -729 | -686 | -648 | -613 | -575 | -531 | -502 | -464 | -437 | -407 | -385 | -366 | -349 | -335 | -320 |
Additional Paid-In Capital | 0.4% | 1,004 | 999 | 995 | 990 | 986 | 980 | 976 | 970 | 965 | 960 | 955 | 946 | 937 | 930 | 720 | 713 | 561 | 531 | 528 | 524 | 523 |
Shares Outstanding | 0.4% | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | 152 | - | - | - | 115 | - | - | - | 320 | - | - | - | 1,500 | - | - | - | 675 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 10.8% | -21,328 | -23,913 | -23,249 | -22,412 | -18,475 | -31,808 | -28,879 | -28,929 | -25,815 | -25,796 | -33,915 | -22,305 | -22,224 | -26,544 | -16,907 | -13,616 | -14,835 | -9,530 | -11,588 | -13,217 | -12,730 |
Share Based Compensation | -5.5% | 4,148 | 4,389 | 4,469 | 4,563 | 5,253 | 4,503 | 4,942 | 5,381 | 4,410 | 5,326 | 8,234 | 7,224 | 6,177 | 6,020 | 4,785 | 3,409 | 2,850 | 2,661 | 2,626 | 1,762 | 1,182 |
Cashflow From Investing | -154.3% | -9,878 | 18,197 | 67,023 | 21,533 | 2,234 | 24,368 | 30,735 | 84,383 | 23,883 | 10,470 | 37,777 | 6,579 | 11,576 | -132,373 | -88,627 | -70,743 | -19,210 | -15,016 | -36,592 | 2,745 | 8,027 |
Cashflow From Financing | 258.1% | 166 | -105 | 8.00 | - | 242 | - | 362 | 3.00 | 375 | - | 517 | 1,505 | 376 | 204,254 | 2,731 | 148,624 | 26,771 | -91.00 | 1,881 | -370 | -21.00 |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||
License revenue | $ 3,600 | $ 0 |
Operating expenses: | ||
Research and development | 77,676 | 99,277 |
General and administrative | 49,915 | 57,858 |
Total operating expenses | 127,591 | 157,135 |
Operating loss | (123,991) | (157,135) |
Other income, net | 5,748 | 2,673 |
Net loss before income taxes | (118,243) | (154,462) |
Income tax benefit (provision) | 1,078 | (74) |
Net loss | (117,165) | (154,536) |
Other comprehensive loss: | ||
Net unrealized gain (loss) on marketable securities | 1,057 | (788) |
Foreign currency translation adjustment | 1 | (29) |
Comprehensive loss | $ (116,107) | $ (155,353) |
Net loss per share - basic (in USD per share) | $ (1.16) | $ (1.56) |
Net loss per share - diluted (in USD per share) | $ (1.16) | $ (1.56) |
Weighted-average common shares outstanding - basic (in shares) | 100,824 | 99,251 |
Weighted-average common shares outstanding - diluted (in shares) | 100,824 | 99,251 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 75,000 | $ 68,431 |
Short-term investments | 21,526 | 117,158 |
Prepaid expenses and other current assets | 6,247 | 5,006 |
Total current assets | 102,773 | 190,595 |
Operating lease right-of-use assets | 52,266 | 78,934 |
Property and equipment, net | 14,764 | 34,927 |
Restricted cash | 1,976 | 2,503 |
Deposit and other long-term assets | 1,231 | 1,413 |
Total assets | 173,010 | 308,372 |
Current liabilities: | ||
Accounts payable | 1,921 | 2,238 |
Accrued expenses and other current liabilities | 12,584 | 16,767 |
Lease liability, current portion | 10,409 | 13,241 |
Total current liabilities | 24,914 | 32,246 |
Long-term liabilities: | ||
Lease liability, net of current portion | 64,627 | 93,561 |
Other non-current liabilities | 0 | 1,047 |
Total liabilities | 89,541 | 126,854 |
Commitments and contingencies (Note 7) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value, 5,000 shares authorized; no shares issued and outstanding | 0 | 0 |
Common stock, $0.0001 par value, 300,000 shares authorized at December 31, 2023: 101,433 and 100,117 shares issued and outstanding at December 31, 2023 and 2022, respectively | 10 | 10 |
Additional paid-in capital | 1,003,709 | 985,651 |
Accumulated other comprehensive loss | (473) | (1,531) |
Accumulated deficit | (919,777) | (802,612) |
Total stockholders’ equity | 83,469 | 181,518 |
Total liabilities and stockholders’ equity | $ 173,010 | $ 308,372 |